Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.68
NVSEF's Cash to Debt is ranked lower than
57% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.03 vs. NVSEF: 0.68 )
Ranked among companies with meaningful Cash to Debt only.
NVSEF' s 10-Year Cash to Debt Range
Min: 0.25   Max: 3.39
Current: 0.68

0.25
3.39
Equity to Asset 0.56
NVSEF's Equity to Asset is ranked higher than
61% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.43 vs. NVSEF: 0.56 )
Ranked among companies with meaningful Equity to Asset only.
NVSEF' s 10-Year Equity to Asset Range
Min: 0.51   Max: 0.65
Current: 0.56

0.51
0.65
Interest Coverage 15.75
NVSEF's Interest Coverage is ranked higher than
68% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. NVSEF: 15.75 )
Ranked among companies with meaningful Interest Coverage only.
NVSEF' s 10-Year Interest Coverage Range
Min: 13.56   Max: 30.91
Current: 15.75

13.56
30.91
F-Score: 6
Z-Score: 4.28
M-Score: -2.81
WACC vs ROIC
8.26%
11.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 20.91
NVSEF's Operating margin (%) is ranked higher than
87% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.69 vs. NVSEF: 20.91 )
Ranked among companies with meaningful Operating margin (%) only.
NVSEF' s 10-Year Operating margin (%) Range
Min: 17.81   Max: 24.34
Current: 20.91

17.81
24.34
Net-margin (%) 39.05
NVSEF's Net-margin (%) is ranked higher than
97% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.76 vs. NVSEF: 39.05 )
Ranked among companies with meaningful Net-margin (%) only.
NVSEF' s 10-Year Net-margin (%) Range
Min: 15.35   Max: 31.38
Current: 39.05

15.35
31.38
ROE (%) 29.05
NVSEF's ROE (%) is ranked higher than
92% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.48 vs. NVSEF: 29.05 )
Ranked among companies with meaningful ROE (%) only.
NVSEF' s 10-Year ROE (%) Range
Min: 12.6   Max: 25.73
Current: 29.05

12.6
25.73
ROA (%) 16.39
NVSEF's ROA (%) is ranked higher than
91% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.45 vs. NVSEF: 16.39 )
Ranked among companies with meaningful ROA (%) only.
NVSEF' s 10-Year ROA (%) Range
Min: 7.21   Max: 16.18
Current: 16.39

7.21
16.18
ROC (Joel Greenblatt) (%) 54.59
NVSEF's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.04 vs. NVSEF: 54.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVSEF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 38.42   Max: 74.09
Current: 54.59

38.42
74.09
Revenue Growth (3Y)(%) -2.00
NVSEF's Revenue Growth (3Y)(%) is ranked higher than
55% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.40 vs. NVSEF: -2.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVSEF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -3.9   Max: 73.5
Current: -2

-3.9
73.5
EBITDA Growth (3Y)(%) 5.40
NVSEF's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -31.90 vs. NVSEF: 5.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVSEF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -7   Max: 82.8
Current: 5.4

-7
82.8
EPS Growth (3Y)(%) 6.00
NVSEF's EPS Growth (3Y)(%) is ranked higher than
76% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -53.60 vs. NVSEF: 6.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVSEF' s 10-Year EPS Growth (3Y)(%) Range
Min: -7.2   Max: 82.2
Current: 6

-7.2
82.2
» NVSEF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NVSEF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 25.90
NVSEF's P/E(ttm) is ranked higher than
76% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 83.70 vs. NVSEF: 25.90 )
Ranked among companies with meaningful P/E(ttm) only.
NVSEF' s 10-Year P/E(ttm) Range
Min: 7.87   Max: 26.66
Current: 25.9

7.87
26.66
Forward P/E 19.16
NVSEF's Forward P/E is ranked higher than
92% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 129.87 vs. NVSEF: 19.16 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.40
NVSEF's PE(NRI) is ranked higher than
81% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 169.30 vs. NVSEF: 23.40 )
Ranked among companies with meaningful PE(NRI) only.
NVSEF' s 10-Year PE(NRI) Range
Min: 10.63   Max: 24.89
Current: 23.4

10.63
24.89
P/B 3.20
NVSEF's P/B is ranked higher than
55% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. NVSEF: 3.20 )
Ranked among companies with meaningful P/B only.
NVSEF' s 10-Year P/B Range
Min: 1.69   Max: 4.14
Current: 3.2

1.69
4.14
P/S 4.70
NVSEF's P/S is ranked higher than
74% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. NVSEF: 4.70 )
Ranked among companies with meaningful P/S only.
NVSEF' s 10-Year P/S Range
Min: 1.89   Max: 4.92
Current: 4.7

1.89
4.92
PFCF 24.30
NVSEF's PFCF is ranked higher than
83% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 491.77 vs. NVSEF: 24.30 )
Ranked among companies with meaningful PFCF only.
NVSEF' s 10-Year PFCF Range
Min: 7.03   Max: 26.79
Current: 24.3

7.03
26.79
POCF 18.41
NVSEF's POCF is ranked higher than
80% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 160.87 vs. NVSEF: 18.41 )
Ranked among companies with meaningful POCF only.
NVSEF' s 10-Year POCF Range
Min: 5.75   Max: 19.28
Current: 18.41

5.75
19.28
EV-to-EBIT 22.41
NVSEF's EV-to-EBIT is ranked higher than
75% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 139.28 vs. NVSEF: 22.41 )
Ranked among companies with meaningful EV-to-EBIT only.
NVSEF' s 10-Year EV-to-EBIT Range
Min: 8.9   Max: 23.2
Current: 22.41

8.9
23.2
Shiller P/E 25.10
NVSEF's Shiller P/E is ranked higher than
84% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. NVSEF: 25.10 )
Ranked among companies with meaningful Shiller P/E only.
NVSEF' s 10-Year Shiller P/E Range
Min: 9.22   Max: 25.93
Current: 25.1

9.22
25.93
Current Ratio 1.39
NVSEF's Current Ratio is ranked lower than
53% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. NVSEF: 1.39 )
Ranked among companies with meaningful Current Ratio only.
NVSEF' s 10-Year Current Ratio Range
Min: 1.04   Max: 2.83
Current: 1.39

1.04
2.83
Quick Ratio 1.17
NVSEF's Quick Ratio is ranked higher than
51% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.15 vs. NVSEF: 1.17 )
Ranked among companies with meaningful Quick Ratio only.
NVSEF' s 10-Year Quick Ratio Range
Min: 0.78   Max: 2.48
Current: 1.17

0.78
2.48
Days Inventory 140.32
NVSEF's Days Inventory is ranked higher than
53% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 151.00 vs. NVSEF: 140.32 )
Ranked among companies with meaningful Days Inventory only.
NVSEF' s 10-Year Days Inventory Range
Min: 117.86   Max: 297.21
Current: 140.32

117.86
297.21
Days Sales Outstanding 62.95
NVSEF's Days Sales Outstanding is ranked higher than
70% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.78 vs. NVSEF: 62.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVSEF' s 10-Year Days Sales Outstanding Range
Min: 53.85   Max: 79.16
Current: 62.95

53.85
79.16

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.60
NVSEF's Dividend Yield is ranked higher than
95% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.82 vs. NVSEF: 2.60 )
Ranked among companies with meaningful Dividend Yield only.
NVSEF' s 10-Year Dividend Yield Range
Min: 1.47   Max: 5.11
Current: 2.6

1.47
5.11
Dividend Payout 0.64
NVSEF's Dividend Payout is ranked higher than
90% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. NVSEF: 0.64 )
Ranked among companies with meaningful Dividend Payout only.
NVSEF' s 10-Year Dividend Payout Range
Min: 0.22   Max: 0.67
Current: 0.64

0.22
0.67
Dividend growth (3y) 6.80
NVSEF's Dividend growth (3y) is ranked higher than
86% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. NVSEF: 6.80 )
Ranked among companies with meaningful Dividend growth (3y) only.
NVSEF' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 18.5
Current: 6.8

0
18.5
Yield on cost (5-Year) 3.93
NVSEF's Yield on cost (5-Year) is ranked higher than
95% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. NVSEF: 3.93 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVSEF' s 10-Year Yield on cost (5-Year) Range
Min: 2.14   Max: 7.44
Current: 3.93

2.14
7.44
Share Buyback Rate -0.20
NVSEF's Share Buyback Rate is ranked higher than
86% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. NVSEF: -0.20 )
Ranked among companies with meaningful Share Buyback Rate only.
NVSEF' s 10-Year Share Buyback Rate Range
Min: 41.9   Max: -2.5
Current: -0.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 27.80
NVSEF's Price/Tangible Book is ranked lower than
97% of the 824 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.50 vs. NVSEF: 27.80 )
Ranked among companies with meaningful Price/Tangible Book only.
NVSEF' s 10-Year Price/Tangible Book Range
Min: 0.16   Max: 35.33
Current: 27.8

0.16
35.33
Price/DCF (Projected) 1.60
NVSEF's Price/DCF (Projected) is ranked higher than
86% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. NVSEF: 1.60 )
Ranked among companies with meaningful Price/DCF (Projected) only.
NVSEF' s 10-Year Price/DCF (Projected) Range
Min: 0.76   Max: 1.53
Current: 1.6

0.76
1.53
Price/Median PS Value 1.60
NVSEF's Price/Median PS Value is ranked higher than
50% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. NVSEF: 1.60 )
Ranked among companies with meaningful Price/Median PS Value only.
NVSEF' s 10-Year Price/Median PS Value Range
Min: 0.75   Max: 1.69
Current: 1.6

0.75
1.69
Price/Graham Number 3.80
NVSEF's Price/Graham Number is ranked higher than
61% of the 830 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. NVSEF: 3.80 )
Ranked among companies with meaningful Price/Graham Number only.
NVSEF' s 10-Year Price/Graham Number Range
Min: 0.07   Max: 4.84
Current: 3.8

0.07
4.84
Earnings Yield (Greenblatt) 4.40
NVSEF's Earnings Yield (Greenblatt) is ranked higher than
72% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. NVSEF: 4.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
NVSEF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.3   Max: 11.3
Current: 4.4

4.3
11.3
Forward Rate of Return (Yacktman) 1.51
NVSEF's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. NVSEF: 1.51 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
NVSEF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 1.3   Max: 81.5
Current: 1.51

1.3
81.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, ABT » details
Traded in other countries:0HKE.UK, NOVN.Switzerland, NVS.USA, NOT.Germany, NOTA.Germany, NVS N.Mexico, NVS.Argentina, NOVNEE.Switzerland,
Novartis AG was incorporated on February 29, 1996 under the Swiss laws. On December 20, 1996, its predecessor companies, Ciba-Geigy AG and Sandoz AG, merged into this new entity, creating Novartis. The Company is engaged in the research, development, manufacturing and marketing of healthcare and pharmaceuticals products. The Company's portfolio includes innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company's wholly-owned businesses are organized into six global operating divisions, and they report teir results in the following five segments; Pharmaceuticals: Innovative patent-protected prescription medicines, Alcon: Surgical, ophthalmic pharmaceutical and vision care products, Sandoz: Generic pharmaceuticals, Vaccines and Diagnostics: Preventive human vaccines and blood testing diagnostics, Consumer Health: OTC (over-the-counter medicines) and Animal Health. The Pharmaceuticals division researches, develops, manufactures, distributes and sells patented prescription medicines and is organized in the following business franchises: Primary Care, consisting of Primary Care medicines and Established Medicines; and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The manufacture of the products is complex and heavily regulated by governmental health authorities, which means that supply is never guaranteed. If the Company or its third party suppliers fail to comply with applicable regulations then there could be a product recall or other shutdown or disruption of its production activities. The Company is subject to the laws of Switzerland, in particular Swiss company and securities laws, and to the securities laws of the United States as applicable to foreign private issuers of securities.
» More Articles for NVSEF

Headlines

Articles On GuruFocus.com
Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
8 Top Healthcare Stocks to Watch May 13 2015 
Amgen Reports An Upbeat Q1 Earnings Apr 23 2015 
Top Weighted Stocks in Tweedy Browne Global Value Fund's Portfolio Apr 22 2015 
Amgen’s Q1 Earnings Paints An Overall Positive Image To Investors Apr 22 2015 
In Europe Really Recovering? Apr 19 2015 
Amgen’s First Drug For Cardiovascular Disease Gets The Green Light Apr 17 2015 
Bristol-Myers Signs An Exclusive Pact In Gene Therapy For Treating Cardiovascular Disorders Apr 08 2015 
Biotech Momentum Indicators: Achaogen (AKAO), Novartis (NVS), VIVUS (VVUS) Apr 01 2015 
Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 

More From Other Websites
Early movers: TIF, KORS, TOL, BWS, HRL & more May 27 2015
Novartis digs into health tech with bet on "robotic pill" May 27 2015
Novartis digs into health tech with bet on 'robotic pill' May 27 2015
Novartis digs into health tech with bet on "robotic pill" May 27 2015
Novartis Announces Positive Data on Oncology Drug Afinitor - Analyst Blog May 22 2015
Novartis' Summer Blockbuster LCZ696 Gains A Name, Skips An Advisory Panel May 22 2015
Buckingham's Top Four New Buys of First Quarter Go Up in Price May 15 2015
GSK's Curious Oncology Research Position -- A Recipe For Failure? May 12 2015
Novartis' Zykadia Approved in the EU for Lung Cancer - Analyst Blog May 11 2015
​Amgen wins injunction against Novartis' biosimilar drug May 08 2015
Pharmalot.. Pharmalittle.. As the Weekend Nears: We're Catching up on Amgen, Sanofi and Much More!! May 08 2015
[$$] Business Watch: News Digest May 08 2015
Novartis 'biosimilar' drug blocked by U.S. appeals court May 07 2015
Glaxo's (GSK) Q1 Earnings Fall Y/Y; Gives Five-Year View - Analyst Blog May 07 2015
Novartis AG's 'biosimilar' drug sale blocked by U.S. appeals court May 07 2015
Court Blocks Novartis Copy of Amgen Cancer-Care Drug May 07 2015
Today's Top 5 Stock Picks: Undervalued Large-Caps May 06 2015
GSK's Sturdy Strategy Leaves Investors Waiting May 06 2015
GlaxoSmithKline Won't Sell Its HIV Drugs Unit, Cuts Shareholder Payout May 06 2015
Glaxo Q1 Earnings Miss, But 5-Year Guidance Strong May 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK